Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial.
A controlled clinical trial is in progress to assess the value of hyperbaric oxygen and radiotherapy in the management of head and neck cancer. An established dose-fractionation schedule in hyperbaric oxygen is being compared with a widely used conventional schedule in air. Survival and local recurrence-free rates are significantly higher in the oxygen group, and the effects on normal tissue are similar in both groups. These findings suggest a genuine therapeutic advantage. There was a distinct improvement in the results of treating advanced laryngeal carcinoma, where there was a high survival rate, without resort to laryngectomy.
D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D006931:Hyperbaric Oxygenation; D007822:Laryngeal Neoplasms / Q000628:therapy; D009062:Mouth Neoplasms / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009669:Nose Neoplasms / Q000628:therapy; D010610:Pharyngeal Neoplasms / Q000628:therapy; D011879:Radiotherapy Dosage